Inspira Technologies Partners with Westchester Medical Center
Ticker: IINNW · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1837493
| Field | Detail |
|---|---|
| Company | Inspira Technologies Oxy B.H.N. LTD (IINNW) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: collaboration, medical-device, clinical-trial
TL;DR
Inspira teams up with Westchester Medical Center to test their ART100 device in clinical settings.
AI Summary
Inspira Technologies Oxy B.H.N. Ltd. announced on December 4, 2024, a collaboration with Westchester Medical Center in New York. This partnership aims to evaluate the functionality and performance of Inspira's ART100 device in real-world clinical scenarios. The collaboration is detailed in a press release furnished as Exhibit 99.1 with their Form 6-K filing.
Why It Matters
This collaboration could validate the clinical utility of Inspira's ART100 device, potentially leading to wider adoption and improved patient care in interventional cardiology.
Risk Assessment
Risk Level: medium — The filing indicates a collaboration for evaluation, but does not guarantee commercial success or regulatory approval for the ART100 device.
Key Players & Entities
- Inspira Technologies Oxy B.H.N. Ltd. (company) — Registrant
- Westchester Medical Center (company) — Collaborating institution
- ART100 (product) — Device being evaluated
- December 4, 2024 (date) — Date of press release
FAQ
What is the primary objective of the collaboration between Inspira Technologies and Westchester Medical Center?
The primary objective is to evaluate the functionality and performance of the Inspira ART100 device in clinical scenarios.
When was the press release announcing this collaboration issued?
The press release was issued on December 4, 2024.
Which specific device is being evaluated in this collaboration?
The Inspira ART100 device is being evaluated.
Where is Westchester Medical Center located?
Westchester Medical Center is located in New York.
Under which form is this report being filed?
This report is being filed on Form 6-K.
Filing Stats: 315 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2024-12-04 07:05:10
Filing Documents
- ea0223523-6k_inspira.htm (6-K) — 11KB
- ea022352301ex99-1_inspira.htm (EX-99.1) — 13KB
- 0001213900-24-105238.txt ( ) — 25KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Inspira Technologies Oxy B.H.N. Ltd. Date: December 4, 2024 By: /s/ Dagi Ben-Noon Name: Dagi Ben-Noon Title: Chief Executive Officer 2